A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
Categories (click each to see list of all clinical trials associated with that category): FPBCC CTO Studies, Lymphoma/CLL (ONC)
Current Status: Open
Phase: I (Cancer Control)
Principal Investigator: Lunning, Matthew
Contact Information:
Debbie Vidlak
dvidlak@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT05512390?term=NCT05512390&rank=1#participation-criteria
Summary
Primary: To evaluate the safety, tolerability, PK, immunogenicity and identify an RP2D of
ABBV-319
Secondary: To evaluate the efficacy of ABBV-319 administered to participants with R/R DLBCL, FL, and CLL
Exploratory: To evaluate the effect of ABBV-319 administration on QT prolongation; To evaluate PD and predictive biomarkers.